Glaukos registers $86.25 million of stock for initial public offering

IPO conducted by JPMorgan, BofA Merrill Lynch and Goldman Sachs

By Devika Patel

Knoxville, Tenn., May 12 – Glaukos Corp. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock for the deal.

J.P. Morgan Securities LLC, BofA Merrill Lynch and Goldman Sachs & Co. are the bookrunners, and William Blair & Co., LLC and Cantor Fitzgerald & Co. are the co-managers.

Proceeds will be used to hire additional sales, marketing and customer service personnel and expand marketing programs; for clinical studies; to purchase intellectual property and other assets; and for working capital and other general corporate purposes.

The ophthalmic medical technology company is based in Laguna Hills, Calif. The company intends to list its common stock on the NYSE exchange under the symbol “GKOS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.